The tyrosine kinase inhibitor nintedanib (Ofev) has been listed on the PBS for the treatment of idiopathic pulmonary fibrosis. The listing is the first subsidised therapy for people living with the condition. Patients will be able to access the drug through the PBS if they have been diagnosed with IPF through multidisciplinary discussion, had an high ...
Already a member?
Enter your email to keep reading.